Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis

Nezu, Saeko; Tanaka, Atsushi; Yasui, Hiroaki; Imamura, Makiko; Nakajima, Hiroshi; Ishida, Hideyuki; Takahashi, Shinichi

doi:10.1111/j.1440-1746.2006.04434.x

Cited by 47 publications

(28 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results suggested that PBC patients representing with negative AMA is also a subpopulation of AMA-positive PBC patients in China. Surprisingly, 15.9% of the AIH patients we studied were AMA-positive, and that was lower than the 34% positive value described in a Japanese population [20]. Based on a previous study that described fluctuating AMA levels in AIH patients over time [21], we considered this possibility in the Chinese patients described here as an explanation for the reduced levels observed.…”

Section: Discussioncontrasting

confidence: 51%

Prevalence of Autoimmune Liver Disease Related Autoantibodies in Chinese Patients with Primary Biliary Cirrhosis

Deng

Song

et al. 2011

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 51%

Prevalence of Autoimmune Liver Disease Related Autoantibodies in Chinese Patients with Primary Biliary Cirrhosis

Deng

Song

et al. 2011

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

“…Disease controls consisted of 5 groups: autoimmune hepatitis (AIH) (281), primary sclerosing cholangitis (PSC) (77), viral hepatitis (189), other liver diseases (31), and other infectious or autoimmune diseases (AID) (30). The diagnosis of AIH was made according to internationally recognized criteria [19]; the diagnosis of PSC was established based on diagnostic features shown by endoscopic retrograde cholangiography or magnetic resonance cholangiopancreatograpgy [5,20].…”

Section: Subjectsmentioning

confidence: 99%

PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis

Liu

Norman

Shums

et al. 2010

Journal of Autoimmunity

128

View full text Add to dashboard Cite

“…The universal availability and superior sensitivity of assays for ANA, SMA, and anti-LKM1 for autoimmune hepatitis justify their use as the first-line testing battery [1,10]. Antimitochondrial antibodies (AMA) are highly specific serological markers for primary biliary cirrhosis (PBC) [10], but they can occur in otherwise classical autoimmune hepatitis [34][35][36][37][38][39]. To avoid diagnostic confusion, the absence of AMA is an appropriate diagnostic requisite for autoantibody-negative autoimmune hepatitis in addition to the absence of ANA, SMA, and anti-LKM1.…”

mentioning

confidence: 99%

Autoantibody-Negative Autoimmune Hepatitis

Czaja

2011

Dig Dis Sci

View full text Add to dashboard Cite

Autoimmune hepatitis has a variable clinical phenotype, and the absence of conventional autoantibodies does not preclude its diagnosis or need for treatment. The goals of this review are to describe the frequency and nature of autoantibody-negative autoimmune hepatitis, indicate its outcome after corticosteroid treatment, and increase awareness of the diagnosis in patients with unexplained acute and chronic hepatitis. The frequency of presumed autoantibody-negative autoimmune hepatitis in patients with acute and acute severe presentations is ≤7%, and its frequency in patients with chronic presentations is 1-34%. Patients with acute presentations can have normal serum γ-globulin levels, centrilobular zone 3 necrosis, and low pre-treatment international diagnostic scores. Liver tissue examination is essential for the diagnosis, and hepatic steatosis can be a co-morbid feature. The comprehensive international scoring system can support but never override the clinical diagnosis pre-treatment, and non-standard serological markers should be sought if the clinical diagnosis is uncertain or the diagnostic score is low. A 3-month treatment trial with corticosteroids should be considered in all patients, regardless of the serological findings, and improvements have occurred in 67-87% of cases. Autoantibody-negative autoimmune hepatitis may be associated with an autoantibody outside the conventional battery; it may have a signature autoantibody that is still undiscovered, or its characteristic autoantibodies may have been suppressed or have a delayed expression. The pathogenic mechanisms are presumed to be identical to those of classical disease. Autoantibody-negative autoimmune hepatitis is an infrequent but treatable disease that must be considered in unexplained acute and chronic hepatitis.

show abstract

Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis

Abstract: Antimitochondrial autoantibodies were found to be present in sera of patients with AIH more frequently than expected, even at very low titer. However, clinical features and histological findings of AIH were not influenced by the AMA status.

Cited by 47 publications

References 32 publications

Prevalence of Autoimmune Liver Disease Related Autoantibodies in Chinese Patients with Primary Biliary Cirrhosis

Prevalence of Autoimmune Liver Disease Related Autoantibodies in Chinese Patients with Primary Biliary Cirrhosis

PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis

Autoantibody-Negative Autoimmune Hepatitis

Contact Info

Product

Resources

About